Prelude Therapeutics Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021; filed March 17, 2022. The filing reports annual results, not separate fourth-quarter results. Prelude is a clinical-stage oncology company with no approved products and no product revenue.
Business context and pipeline
The company’s wholly owned pipeline comprised four clinical-stage candidates and two preclinical programs. Its lead candidates target PRMT5 (PRT543 and brain-penetrant PRT811); other clinical programs target MCL1 (PRT1419) and CDK9 (PRT2527). Preclinical programs include a brain-penetrant CDK4/6 inhibitor, PRT3645, and SMARCA2 protein degraders.
Financial results and liquidity
| Metric (USD millions, except per-share data) | FY2021 | FY2020 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | 86.8 | 48.2 |
| General and administrative expense | 27.0 | 10.6 |
| Total operating expenses / operating loss | 113.7 | 58.8 |
| Other income, net | 2.0 | 1.8 |
| Net loss | 111.7 | 56.9 |
| Basic and diluted net loss per share | $2.43 | $4.56 |
| Net cash used in operating activities | 83.5 | 46.2 |
R&D expense rose 80% and G&A expense rose 155% year over year, primarily reflecting expanded clinical and discovery work, increased headcount, and public-company costs. Stock-based compensation was $20.9 million, versus $5.6 million in 2020. Margins are not meaningful because the company had no revenue.
At December 31, 2021, cash and cash equivalents were $31.8 million, marketable securities were $259.4 million, and restricted cash was $4.0 million. Cash, cash equivalents, and marketable securities totaled $291.2 million, excluding restricted cash. Current assets were $295.1 million and current liabilities $19.2 million. Total liabilities were $19.2 million, principally accounts payable, accruals, and lease liabilities; the filing reports no debt balance. Accumulated deficit was $219.1 million and stockholders’ equity was $285.9 million.
Investing activities used $263.8 million, mainly for $261.5 million of marketable-security purchases and $2.3 million of property and equipment. Financing activities provided $164.9 million, primarily from a January 2021 stock offering that generated $161.4 million net. Year-end marketable securities had $0.7 million of gross unrealized losses; management considered the losses temporary and expected to hold the securities to maturity.
Management stated that existing cash, cash equivalents, and marketable securities were expected to fund operating expenses and capital expenditures into the second half of 2024. This runway estimate depends on assumptions that may prove inaccurate. The company reported no committed credit facility or committed capital source and expects to need additional funding thereafter.
Material developments and outlook
- In March 2022, after the reporting date, Prelude said it would concentrate PRMT5 development on PRT811 in biomarker-selected populations, citing its safety profile, target engagement, and brain penetration. Planned focus areas included spliceosome-mutated cancers, uveal melanoma, and IDH1-mutated high-grade glioma. Expansion-cohort data were anticipated in the second half of 2022; ACC cohort analysis was expected by mid-year.
- Also after year-end, the company prioritized intravenous PRT1419 over its oral formulation and planned a venetoclax combination trial by mid-2022, with a goal of establishing a recommended Phase 2 dose in the second half of 2022.
- Management planned to complete PRT2527 Phase 1 dose escalation and identify a recommended Phase 2 dose in the second half of 2022; file an IND and initiate a PRT3645 Phase 1 trial in the second half of 2022; and submit an IND for the SMARCA2 degrader program by year-end 2022.
- Clinical evidence described in the filing was preliminary and from early-stage trials. PRT543 and PRT811 showed target engagement and isolated signs of activity, but the company cautioned that early results may not predict later trials or establish efficacy. Reported grade 3 or higher treatment-related events included thrombocytopenia and anemia for PRT543, and thrombocytopenia for PRT811.
Risks, contingencies, and unusual items
- All candidates remained investigational; development, regulatory approval, and commercialization are uncertain. The company had incurred recurring losses, had no revenue, and expected losses to continue.
- Funding, trial enrollment, safety, competition, regulatory review, and the ability to obtain adequate reimbursement could materially affect development and the company’s prospects. COVID-19 had caused limited trial-site and enrollment delays, with further effects uncertain.
- Prelude relies on third parties for clinical trials and manufacturing, had no long-term supply arrangements, and lacked redundant supply for certain materials. Supply or contractor problems could delay programs or increase costs.
- A November 2021 lease for approximately 81,000 square feet of office and laboratory space carries an initial 162-month term. Estimated rent over the initial term was approximately $33.8 million; the filing’s contractual-obligations table reported $35.9 million of operating-lease payments in total, including existing leases.
- The company reported no material pending legal proceedings. The financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not engaged to attest to internal-control effectiveness.
Most important facts for investors to verify
- Whether subsequent PRT811 and PRT543 expansion-cohort results support the biomarker-selected strategy, including durability, response rates, and safety.
- Whether the stated cash runway into the second half of 2024 remains supported by current spending, trial plans, and financing needs.
- Execution and clinical differentiation of IV PRT1419, its planned venetoclax combination, and the PRT2527, PRT3645, and SMARCA2 development timelines.
- Marketable-security balances and valuation, restricted cash terms, and the commencement and cash impact of the Chestnut Run lease.
- Clinical-supply continuity and reliance on third-party manufacturers, CROs, and trial sites.